With their push to end smoking in Atlantic City's casinos going nowhere fast in either the courts or the state Legislature, casino workers and supporters of smoke-free gambling halls demonstrated ...

The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

Johnson & Johnson (JNJ) said that Health Canada has issued a Notice of Compliance for CARVYKTI (ciltacabtagene autoleucel) for the ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting ...

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

作为长期战略的一部分，传奇生物在进一步扩大产能的同时，也在积极推进研发项目，以巩固其在细胞治疗创新领域的领导地位。该公司计划在美国宾夕法尼亚州费城新建全球领先的细胞疗法研发设施，预计该设施将于2025年第三季度完工。外界认为，这将进一步扩展传奇生物在 ...

CAR-T（嵌合抗原受体T细胞）疗法是基因工程和免疫学结合而产生的新型疗法。它的基本原理在于抽取患者自身的T细胞，通过基因工程改造之后再将其注入体内，让这些细胞能够识别并攻击癌细胞。传统化疗和放疗方式在对抗恶性肿瘤时常常无法避免地损伤正常细胞，而CAR-T疗法的出现，展现了更高的靶向性和有效性。